Myocet Plus Endoxan for Older Patients With Breast Cancer

Mise à jour : Il y a 4 ans
Référence : NCT01120171

Femme Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

This study will evaluate the efficacy, safety and effect on quality of life of liposomal-encapsulated doxorubicin in combination with cyclophosphamide as first or second line treatment of older patients (≥ 70 years old) with metastatic breast cancer. The efficacy of the combination will be correlated with the functional status of patients according to the comprehensive geriatric assessment


Critère d'inclusion

  • Breast Cancer

Liens